flutiform k-haler is now available in Europe as an asthma treatment for adults and adolescents (aged 12 years and older) [1] Research indicates that many patients make errors with their inhalers and ...

Vectura's Flutiform (fluticasone+formoterol) has failed in a phase 3 chronic obstructive pulmonary disease trial, preventing a filing in Europe. Development partner Mundipharma said that the trial did ...

The European Medicines Agency (EMA) has approved Flutiform pMDI for use in the treatment of children with asthma aged five years and over. The European Medicines Agency (EMA) has approved Flutiform ...

Weak Phase III data have dealt a blow to Vectura’s (LON:VEC) hopes of seeing Flutiform approved for use in chronic obstructive pulmonary disease (COPD) patients. Vectura shares fell as much as 10% ...

LONDON, Aug 21 (Reuters) - British drug delivery specialist SkyePharma trimmed first-half losses on lower revenue and said it remain confident about its key new lung drug Flutiform, despite a delay in ...

Vectura’s hopes of extending the uses of its asthma drug Flutiform into chronic obstructive pulmonary disease (COPD) have been dashed by disappointing phase III data. The UK pharma group saw its ...

LONDON, UK, 1 September 2009 - SkyePharma PLC (LSE: SKP) today provides an update following a meeting held with the US Food and Drug Administration (FDA) to discuss the previously announced potential ...

flutiform is the first pressurised metered-dose inhaler to combine the ICS, fluticasone propionate, with the fast-acting inhaled LABA, formoterol. 2 flutiform is licensed for asthma maintenance ...

SkyePharma says that its development and marketing partner Mundipharma has successfully completed a paediatric study with positive results on its flagship asthma combination drug Flutiform. SkyePharma ...

LONDON, June 24 (Reuters) - Britain's SkyePharma said on Thursday the U.S regulator has set tougher than expected demands for approval of its asthma drug Flutiform, which may prove insurmountable.

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Flutiform" report has been added to ResearchAndMarkets.com's offering. Flutiform ([fluticasone propionate + formoterol fumarate]; ...

flutiform is the first pressurised metered-dose inhaler to combine the ICS, fluticasone propionate, with the fast-acting inhaled LABA, formoterol. 2 flutiform is licensed for asthma maintenance ...